Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Taylor and Francis Group, Leukemia & Lymphoma, 4(63), p. 821-833, 2021

Journal article published in 2021 by Ahmad S. Halwani, Halwani As, Carlos Panizo, Iris Isufi, Alex F. Herrera, Craig Y. Okada, Elizabeth H. Cull, Herrera Af, Jorge M. Chaves, Okada Cy, Bela Kis, Nancy L. Bartlett

, Gottfried R. von Keudell, Cull Eh, Weiyun Ai and other authors.

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by